Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

AHCO May 5, 2026

AdaptHealth Corp Q1 2026 Earnings Call - Largest HME Patient Transition Delivers Revenue Beat, EBITDA Misses on Labor Costs

AdaptHealth delivered a strong revenue beat in Q1 2026, driven by the accelerated rollout of its new capitated contract and solid organic growth across all four segments. The company successfully tran...

  • Q1 2026 net revenue of $819.8 million grew 5.4% year-over-year, exceeding guidance by approximately $22 million, with organic growth accelerating to 9.1%.
  • The company completed the largest patient transition in HME history, moving hundreds of thousands of patients to a new capitated contract ahead of schedule and establishing 35 de novo locations.
  • Capitated revenue surged to $74.9 million, reflecting a seven-fold increase in covered membership to approximately 15 million, now accounting for 9.2% of total consolidated net revenue.
  • +7 more takeaways
PYPL May 5, 2026

PayPal Q1 2026 Earnings Call - New CEO Lores Unveils $1.5B Cost Cuts and Three-Unit Reorg

PayPal’s new CEO Enrique Lores used his first earnings call to lay out a stark turnaround plan. The company is splitting into three focused units—Checkout, Consumer Financial Services (Venmo), and Pay...

  • New CEO Enrique Lores outlines a three-unit organizational structure: Checkout Solutions, Consumer Financial Services (Venmo), and Payment Services (Braintree/Crypto), replacing the previous customer-segment model to eliminate decision-making bottlenecks.
  • PayPal commits to at least $1.5 billion in gross run-rate cost savings over the next two to three years, driven by organizational simplification and aggressive AI adoption across operations and technology development.
  • Lores admits the company over-indexed on merchants in recent years and is now rebalancing investment toward the consumer side to drive habituation, loyalty, and lifetime value through financial services and BNPL.
  • +9 more takeaways
PDYN May 5, 2026

Palladyne AI Q1 2026 Earnings Call - Decentralized Swarming Tech Gains Traction Amid Defense Spending Surge

Palladyne AI reported a 107% year-over-year revenue increase to $3.5 million in Q1 2026, driven by post-acquisition manufacturing and engineering services. The company navigated a federal government s...

  • Revenue surged 107% year-over-year to $3.5 million, with $1.7 million from product manufacturing and $1.8 million from engineering services.
  • Backlog increased to $17 million, up from $13.5 million, reflecting $7 million in new contract awards net of revenue recognized.
  • Full-year 2026 revenue guidance reiterated at $24 million to $27 million, implying 357%-415% growth from 2025.
  • +7 more takeaways
BRCC May 5, 2026

Black Rifle Coffee Company Q1 2026 Earnings Call - Revenue and Earnings Surge on Distribution Gains and Operating Discipline

Black Rifle Coffee Company delivered a robust first quarter in 2026, with net revenue jumping 21% year-over-year to approximately $102 million, driven by a 31.5% surge in wholesale sales and a 7% rebo...

  • Net revenue surged 21% year-over-year, with wholesale sales jumping 31.5% due to broad-based distribution gains and pricing, while direct-to-consumer revenue grew 7% for a second consecutive quarter.
  • The company raised its full-year 2026 revenue guidance to at least 8% growth, targeting approximately $430 million, and increased adjusted EBITDA guidance to at least 35% growth, or roughly $29 million.
  • Adjusted EBITDA expanded by 570 basis points to over $7 million, driven by an 8% reduction in operating expenses and strong revenue growth that translated into higher gross profit dollars.
  • +9 more takeaways
BOW May 5, 2026

Bowhead Specialty Q1 2026 Earnings Call - Digital Underwriting Scales as Casualty Discipline Drives 24% Premium Growth

Bowhead Specialty delivered a forceful start to 2026, with gross written premiums surging 24% to $217 million, driven by disciplined underwriting in casualty and rapid scaling of its digital platforms...

  • Gross written premiums surged 24% year-over-year to $217 million, with casualty driving the largest growth at $147 million, up over 20%.
  • Adjusted net income reached $16 million, a 40% year-over-year increase, with diluted adjusted EPS of $0.48 and adjusted ROAE of 14.1%.
  • The combined ratio stood at 95.3%, with the loss ratio at 66.9% and the expense ratio improving 200 basis points to 28.4%.
  • +12 more takeaways
HSIC May 5, 2026

Henry Schein Q1 2026 Earnings Call - Margin Expansion Driven by Value Creation and AI Adoption

Henry Schein delivered a solid first quarter of 2026, with global sales rising 6.3% to $3.4 billion and non-GAAP diluted EPS climbing to $1.32. The results were anchored by strong momentum in U.S. den...

  • Global sales grew 6.3% year-over-year to $3.4 billion, with local currency internal sales up 2.5% and a 3.1% tailwind from foreign exchange.
  • Non-GAAP diluted EPS reached $1.32, up from $1.15 in the prior year, driven by gross margin expansion and favorable business mix.
  • U.S. dental merchandise sales accelerated 5.6%, with internal growth of 4.1%, as DSOs continue to invest in practice equipment and gain market share.
  • +9 more takeaways
OFIX May 5, 2026

Orthofix International PLC Q1 2026 Earnings Call - Spine Distributor Shift Drives Momentum, Biologics Turnaround Underway

Orthofix International delivered a disciplined start to 2026, with Q1 net sales rising 3% year-over-year to $196.4 million, supported by a strategic pivot toward larger, more dedicated spine distribut...

  • Q1 2026 net sales rose 3% year-over-year to $196.4 million on a pro forma constant currency basis, landing within the range implied by full-year guidance.
  • U.S. spine fixation net sales grew 4%, with the top 30 distributor partners delivering 27% year-over-year growth as the company’s channel transition strategy matures.
  • Management confirmed spine distributor transitions are largely complete, with a new leadership structure simplifying decision-making and bringing oversight closer to the field.
  • +7 more takeaways
SQNS May 5, 2026

Sequans Communications Q1 2026 Earnings Call - Sequans Purges Debt, Holds 600 Bitcoin, and Bets on 5G IoT

Sequans Communications is shedding its crypto-driven debt burden to refocus on its core IoT semiconductor business. The company plans to fully redeem its $94.5 million convertible debt by June 1, 2026...

  • Sequans will fully redeem $94.5 million in convertible debt by June 1, 2026, funded by selling Bitcoin collateral, leaving a near debt-free balance sheet.
  • Post-debt redemption, Sequans will hold at least 600 unencumbered Bitcoin, which management plans to monetize opportunistically rather than reinvest.
  • Q1 2026 revenue was $6.1 million, in line with expectations, driven by product sales despite variability in licensing and service revenue timing.
  • +7 more takeaways
FERG May 5, 2026

Ferguson Q1 2026 Earnings Call - Non-Residential Growth Offsets Weak Residential Amid Inflation and M&A Expansion

Ferguson delivered a solid Q1 2026 performance with sales of $7.5 billion, up 3.6% year-over-year, driven by strong non-residential growth (up 8%) that offset a challenging residential market (down 1%...

  • Sales of $7.5 billion increased 3.6% year-over-year, with 2.8% organic growth and 0.8% from acquisitions.
  • Operating profit grew 8.4%, expanding operating margins by 40 basis points to 8.7%, driving a 9.1% increase in diluted EPS to $2.28.
  • Non-residential revenue surged 8%, significantly outperforming the market, driven by large capital projects and a 18% jump in commercial mechanical sales.
  • +7 more takeaways
FTRE May 5, 2026

Fortrea Holdings Inc Q1 2026 Earnings Call - AI Integration and Biotech Momentum Drive Margin Expansion

Fortrea Holdings delivered a solid first quarter in 2026, marking a strong start with revenue of $636.5 million and adjusted EBITDA of $47 million. The company is on track to meet its full-year guidan...

  • Q1 2026 revenue was $636.5 million, a 2.3% year-over-year decline, primarily driven by lower pass-through costs in clinical pharmacology and clinical development, though underlying full-service clinical revenue grew.
  • Adjusted EBITDA reached $47 million, up from $30.3 million in the prior year period, supported by cost savings initiatives and improved project mix.
  • Book-to-bill ratio was 1.15x for the quarter and 1.05x on a trailing twelve-month basis, reflecting the third consecutive quarter of book-to-bill ratios at or above 1.1x.
  • +12 more takeaways